Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease ; volume:63 ; number:4 ; day:15 ; month:3 ; year:2024 ; pages:529-538 ; date:4.2024
Clinical pharmacokinetics ; 63, Heft 4 (15.3.2024), 529-538, 4.2024
- Urheber
-
Bevers, Nanja C.
Keizer, Ron J.
Wong, Dennis R.
Aliu, Arta
Pierik, Marieke J.
Derijks, Luc J. J.
Rheenen, Patrick F. van
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40262-024-01354-7
- URN
-
urn:nbn:de:101:1-2407092110252.049926877080
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
11.06.2025, 14:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bevers, Nanja C.
- Keizer, Ron J.
- Wong, Dennis R.
- Aliu, Arta
- Pierik, Marieke J.
- Derijks, Luc J. J.
- Rheenen, Patrick F. van
- SpringerLink (Online service)
Ähnliche Objekte (12)
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
![Beyond traditional borders : [eight centuries of Latvian-Dutch relations]](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Beyond traditional borders : [eight centuries of Latvian-Dutch relations]
Pharmacokinetic Effects of Antidrug Antibodies Occurring in Healthy Subjects After a Single Dose of Intravenous Infliximab
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease
High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients
Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
Beyond traditional borders : [eight centuries of Latvian-Dutch relations]
Pharmacokinetic Effects of Antidrug Antibodies Occurring in Healthy Subjects After a Single Dose of Intravenous Infliximab
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease
High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients
Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
Beyond traditional borders : [eight centuries of Latvian-Dutch relations]
Pharmacokinetic Effects of Antidrug Antibodies Occurring in Healthy Subjects After a Single Dose of Intravenous Infliximab
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease
High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients